Navigation Links
Oxygen Biotherapeutics, Inc. Expands Board of Directors

COSTA MESA, Calif., March 20 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced the expansion of the company's board of directors with the addition of J. Melville Engle to the board.

Engle has over 27 years experience in leading both large and small companies. He has raised money on Wall Street, launched hundreds of products, and has a broad management and financial background, including six years at Dey LP, where he was the firm's president and CEO. Dey LP, a Napa, CA-based specialty pharmaceutical company, is focused on the development and commercialization of products for respiratory, allergy and other breathing disorders. Engle's background also includes senior executive positions with Merck Generics Group, a division of Merck KGaA, and Allergan, Inc.

"I'm very pleased that Mel has agreed to join our board," said Chris J. Stern, company chairman and CEO. "He has the business acumen and experience in the pharmaceutical industry to help us develop and grow as we work to bring Oxycyte(R)-based products to the market. During his tenure at Dey, sales increased from $250 million to over $600 million. Our board and company will be stronger with his involvement."

"I'm excited about the promise of Oxycyte and what I can see as the potential for this company. I'm looking forward to working with Chris and the other board members to help bring that potential to reality," said Engle.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, and diabetes. More information is available at

SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
2. Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
3. Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter
4. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
5. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
6. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
7. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
8. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
9. ATS Medical Expands Open Pivot Heart Valve Offerings
10. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
11. BioLife Solutions Expands Scientific Advisory Board
Post Your Comments:
(Date:10/11/2017)... ... 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. ... San Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, ... government officials from around the world to address key issues in device compliance, quality ...
(Date:10/11/2017)... ... , ... Disappearing forests and increased emissions are the main causes of the ... Especially those living in larger cities are affected by air pollution related diseases. , ... pollution-affected countries globally - decided to take action. , “I knew I had to ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
Breaking Biology Technology:
(Date:4/18/2017)... 18, 2017  Socionext Inc., a global expert in SoC-based imaging ... server, the M820, which features the company,s hybrid codec technology. A ... Tera Probe, Inc., will be showcased during the upcoming Medtec Japan ... at the Las Vegas Convention Center April ... Click here for ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
Breaking Biology News(10 mins):